$GRI

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

GRI Bio, Inc. has filed an Amendment No. 2 to a Schedule 13G/A, reporting that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC beneficially own 90,475 shares of common stock, representing a 5.9% stake. These shares are issuable upon the exercise of a warrant held by Intracoastal, based on 1,445,029 shares outstanding as of January 29, 2026. The filing notes two additional warrants with 4.99% blocker provisions, which are excluded from this reported percentage.

GRI Bio, Inc. has announced the receipt of a patent from the UAE Patent Office for its inflammatory disease treatment, covering type 2 diverse NKT cell agonists. This patent strengthens the company's intellectual property and supports its pipeline for inflammatory, fibrotic, and autoimmune diseases, despite significant financial headwinds indicated by a 93.5% drop in share price over the past year. The company is actively working to advance its drug development and improve its financial position, including recent capital raises and a planned reverse stock split.

GRI Bio CEO Marc Hertz discussed additional positive Phase 2a data for idiopathic pulmonary fibrosis (IPF) in a Virtual Investor segment, highlighting biomarker improvements related to fibrosis and lung repair. This announcement reiterates the company's recent focus on its clinical story, following other milestones like a reverse stock split, patent protection, and financial updates. Investors are encouraged to monitor the progression of these Phase 2a results into later-stage trials and the company's capital raising activities.

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data ...

Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET ...

Live video webcast on Wednesday, August 20th at 2:20 PM ET ...

Access the "What This Means" segment here ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 44,566.33 while the NASDAQ rose 1.26% to 21,395.66. The S&P 500 also rose, gaining, 0.76% to 6,411.57.